Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
about
Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control studyEffectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies.Vaccination in HIV-infected adults.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Response to Pneumococcal Polysaccharide Vaccination in HIV-Positive Individuals on Long Term Highly Active Antiretroviral Therapy.Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention.Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: a Belgian consensus report.Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I.HIV-related pneumococcal disease prevention in adults.British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015.Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.No changes on viral load and CD4+ T-cell counts following immunization with 7-valent pneumococcal conjugate vaccine among HIV-infected adults in Malawi.
P2860
Q33303633-549B3929-5C88-407B-8390-E7EDB1EDFDFEQ33719116-B4CCBC14-FED9-4A04-B33B-9D94AF71F694Q33980764-58E741CB-04AC-46E9-9DCA-33C17AD1289BQ34390072-7ED44919-C19B-441C-B812-C983DDE2E150Q35511280-733F2AC4-D6C8-4900-B36C-08218225DA0EQ35874108-07BE4D69-3DD0-464D-9E57-DB8DE6F0E299Q36009704-4FCCE660-4F43-4D52-866F-37A3AA9408F5Q36257961-583B800D-CF18-4D43-804A-4FDA2A0C6073Q36406774-5CCF3A79-1D6A-4FD0-B159-4709BCE2B750Q37384771-826BC979-E7E5-4443-A6C8-8ECFA1C66BD3Q38639401-4D46A82F-B568-4FBE-8F5E-4AC25883364AQ38947827-03CAFBEF-7637-4BC6-873A-629206D1189EQ40560650-F4804395-0104-4F80-825E-9405420BF008Q41662682-73B8497B-51AE-469D-90A3-34B87FAF4C45Q53694026-D7303037-3267-4A53-BF9A-107B2C6931F3
P2860
Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Clinical experience of the 23- ...... ospective observational study.
@en
Clinical experience of the 23- ...... ospective observational study.
@nl
type
label
Clinical experience of the 23- ...... ospective observational study.
@en
Clinical experience of the 23- ...... ospective observational study.
@nl
prefLabel
Clinical experience of the 23- ...... ospective observational study.
@en
Clinical experience of the 23- ...... ospective observational study.
@nl
P2093
P50
P1433
P1476
Clinical experience of the 23- ...... ospective observational study.
@en
P2093
Mao-Yuan Chen
Szu-Min Hsieh
Wang-Hwei Sheng
P304
P356
10.1016/J.VACCINE.2003.10.030
P407
P577
2004-05-01T00:00:00Z